Breast cancer diagnosis marker and application thereof
A breast cancer, biological sample technology, applied in the field of breast cancer diagnostic markers, can solve problems such as high breast cancer risk, and achieve the effect of high accuracy
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0025] Example 1 Determination of the expression level of ADRM1 protein in breast cancer tissue
[0026] (1) Sample collection
[0027] A total of 148 surgically resected tissue samples from breast cancer patients diagnosed by pathology in our hospital were collected. The selection criteria for patients were: breast cancer confirmed by surgical resection and pathology; no radiotherapy, chemotherapy, hormone and biological targeted therapy before operation.
[0028] (2) Immunohistochemical detection
[0029] The breast cancer nest tissue paraffin specimens were sliced continuously at 4 μm, routinely deparaffinized, washed with PBS, and operated according to the instructions of the immunohistochemical kit. The dilution of mouse anti-human ADRM1 was 1:500, and the dilution of mouse anti-human TP53 was 1: 100, the primary antibody was replaced with phosphate buffered saline (PBS) as a negative control. Color was developed with DAB at room temperature for 5-10 minutes, rinsed w...
Embodiment 2
[0040] Differences in the expression of ADRM1 and TP53 genes in breast cancer tissue and normal tissue in embodiment 2
[0041] The UALCAN database (http: / / ualcan.path.uab.edu / index.html) was used to analyze the expression level of ADRM1 in breast cancer. The screening conditions are as follows: gene symbol=ADRM1; TCGA dataset=Breast invasive carcinoma. There were 1097 breast cancer samples and 114 normal tissue samples that met the conditions. The UALCAN database was used to further analyze the relationship between ADRM1 and age, race, lymph node metastasis stage, histological grade and breast cancer classification, as well as its expression in mutant and non-mutant TP53 breast cancer samples. The results are shown in figure 1 .
[0042] Compared with the normal control group, the expression level of ADRM1 was increased in breast cancer patients (pfigure 1 A), and the expression level of ADRM1 was significantly correlated with age, race, lymph node metastasis stage, histolo...
Embodiment 3
[0044] The screening method of the miRNA of embodiment 3 ADRM1 and TP53
[0045] (1) Screening miRNAs that act together on ADRM1 and TP53
[0046] Through online databases miRTarBase (http: / / www.mirbase.org / ), Mirtarbase (http: / / mirtarbase.cuhk.edu.cn / php / index.php), TargetScan (http: / / www.targetscan.org / mamm_31 / ) and TransmiR (http: / / www.cuilab.cn / transmir) predicted the interaction relationship between ADRM1 and TP53 and miRNA. Cytoscape software (www.cytoscape.org / ) was used to construct and visualize the regulatory network of miRNAs on ADRM1 and TP53. It was found that, including hsa-let-7b-5p, hsa-miR-125b-5p, hsa-miR-24-3p, hsa-miR-1233-5p, hsa-miR-5693, hsa-miR-149-3p, hsa-miR-6766-5p, hsa-miR-4728-5p, hsa-miR-6756-5p, hsa-miR-19b-3, hsa-miR-6778-5p, hsa-miR-194-3p, hsa- 15 miRNAs including miR-6785-5p, hsa-miR-19a-3p and hsa-miR-6883-5 jointly target ADRM1 and TP53 ( image 3 ).
[0047] (2) Further screening of miRNAs that act together on ADRM1 and TP53
[0048...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com